Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13418
Full metadata record
DC FieldValueLanguage
dc.contributor.authorO'Sullivan, J Ben
dc.contributor.authorBertram, J Fen
dc.contributor.authorHarrap, Stephen Ben
dc.date.accessioned2015-05-16T03:15:55Z
dc.date.available2015-05-16T03:15:55Z
dc.date.issued1995-06-07en
dc.identifier.citationClinical and Experimental Pharmacology & Physiology; 22(6-7): 463-5en
dc.identifier.govdoc8582104en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13418en
dc.description.abstract1. The long-term reduction in blood pressure following ACE inhibitor treatment in young spontaneously hypertensive rats (SHR) appears to depend on both the kidney and bradykinin. 2. The aim of this experiment was to examine the effects of ACE inhibition and bradykinin on renal morphology and blood pressure in SHR. 3. Between 6 and 10 weeks of age male SHR received one of four treatments: water (n = 26), ramipril (1 mg/kg per day; n = 24), ramipril (1 mg/kg per day) plus Hoe 140 (0.5 mg/kg per day; n = 25) or Hoe 140 (0.5 mg/kg per day; n = 25). 4. Renal medullary and cortical volumes were determined stereologically at 10 and 20 weeks of age. 5. After 4 weeks of treatment, ramipril reduced the size of the renal medulla while Hoe 140 increased medullary volumes compared to control. Ten weeks after treatment was stopped the renal medulla of the ramipril group had returned to normal, however, there was a persistent increase in medullary volume of both Hoe 140 treated groups. 6. Our results imply that bradykinin may influence the size of the renal medulla which may have important effects on the development of hypertension in SHR.en
dc.language.isoenen
dc.subject.otherAdrenergic beta-Antagonists.administration & dosage.pharmacology.therapeutic useen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.administration & dosage.pharmacology.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAntihypertensive Agents.administration & dosage.pharmacology.therapeutic useen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherBradykinin.administration & dosage.analogs & derivatives.metabolism.pharmacology.therapeutic useen
dc.subject.otherBradykinin Receptor Antagonistsen
dc.subject.otherDisease Models, Animalen
dc.subject.otherHypertension.drug therapy.etiology.metabolismen
dc.subject.otherKidney Cortex.drug effects.metabolismen
dc.subject.otherKidney Medulla.drug effects.metabolismen
dc.subject.otherMaleen
dc.subject.otherRamipril.administration & dosage.pharmacology.therapeutic useen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred SHRen
dc.titleRenal medulla and bradykinin during the development of hypertension in SHR.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical and Experimental Pharmacology & Physiologyen
dc.identifier.affiliationDepartment of Medicine, Austin Hospital, University of Melbourne, Victoria, Australiaen
dc.description.pages463-5en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8582104en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Dec 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.